Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Acelyrin Inc (NQ: SLRN )

4.570 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acelyrin Inc

< Previous 1 2 3 4 5 6 Next >
ACELYRIN ONGOING DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options
From Faruqi & Faruqi LLP
Via GlobeNewswire
Lowey Dannenberg Notifies ACELYRIN, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now. 
Via InvestorPlace
ROSEN, A RESPECTED AND LEADING FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ACELYRIN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
From The Rosen Law Firm PA
Via GlobeNewswire
Lowey Dannenberg Notifies ACELYRIN, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Acelyrin, Inc. (NASDAQ:SLRN) Investor Alert: Lawsuit Alleges False and Misleading Statements
San Diego, CA -- (SBWIRE) -- 12/08/2023 -- An investor, who purchased shares of Acelyrin, Inc. (NASDAQ:SLRN), filed a lawsuit over alleged violations of Federal Securities Laws by Acelyrin, Inc.. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal
ACELYRIN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options
From Faruqi & Faruqi LLP
Via GlobeNewswire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
ACELYRIN SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN Investor Announcement: Kessler Topaz Meltzer & Check, LLP Announces January 16, 2024 Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Acelyrin, Inc. (SLRN)
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SLRN STOCK NEWS: Acelyrin, Inc. Shareholders Should Contact Robbins LLP for Information About Their Rights and Remedies in Acelyrin, Inc. Class Action
From Robbins LLP
Via Business Wire
SLRN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
From The Rosen Law Firm PA
Via GlobeNewswire
SLRN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ACELYRIN, Inc. (SLRN)
From Glancy Prongay & Murray LLP
Via Business Wire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Lowey Dannenberg Notifies ACELYRIN, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?
Acelyrin Inc (NASDAQ: SLRN) updated its izokibep clinical development program, including its ongoing global Phase 2b/3 trial for izokibep in  
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.